HARROW INC (HROW)

Company Profile

Harrow, Inc. engages in the development, production, and sale of innovative medications. The company is headquartered in Nashville, Tennessee and currently employs 315 full-time employees. The company went IPO on 2013-02-08. The firm is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. The company provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. The company owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. The company owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. The company owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.

Company Info

HARROW INC

102 Woodmont Blvd, Suite 610

Nashville TENNESSEE 37205

P: 16157334731

CEO: Mark L. Baum

Employees: 315

Website: https://www.harrow.com/